Kanvas Biosciences

Private

Princeton-based spatial biology company building a microbiome drug discovery, screening, and manufacturing platform. Lead candidate KAN-001 is a live biotherapeutic for solid-tumor patients who do not respond to immune checkpoint inhibitors. Spinout from Cornell, founded 2020.

Founders Matthew Cheng

CEO Matthew Cheng

Company

Founded

2020

Headquarters

Princeton, United States

Financials

Total Funding

$71M

Sectors

Healthtech Biotech

kanvasbio.com

Funding History

3 rounds

Series A May 6, 2026

$48M

DCVC (Lead) Lions Capital Bill & Melinda Gates Foundation ATHOS KG Germin8 Ki Tua Fund Pangaea Ventures FemHealth Ventures Triple Impact Capital Uncommon Denominator

Seed Jul 15, 2024

$13M

DCVC (Lead) Lions Capital Pangaea Ventures Innospark Ventures

Seed Sep 15, 2022

$10M

DCVC (Lead) Innospark Ventures

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.